Conditions

close

result 23633 件

JaLCDOI 10.18926/AMO/53521
FullText URL 69_3_145.pdf
Author Ishii, Hiroko| Kamikawa, Shigeshi| Hirohata, Satoshi| Mizutani, Akifumi| Abe, Koji| Seno, Masaharu| Oohashi, Toshitaka| Ninomiya, Yoshifumi|
Abstract Eosinophil cationic protein (ECP) is well known as a cationic protein contained in the basic granules of activated eosinophils. Recent studies have reported that ECP exhibits novel activities on various types of cells, including rat neonatal cardiomyocytes. Here we evaluated the effects of ECP on rat cardiac myoblast H9c2 cells. Our results showed that ECP enhanced the survival of the cells, in part by promoting the ERK and Akt/GSK-3β signaling pathways. ECP attenuated the cytotoxic effects of H2O2 on H9c2 cells as well as the production of reactive oxygen species, the number of apoptotic cells and caspase 3/7 activity in the cells. In conclusion, ECP activated the ERK and Akt/GSK-3β pathways, resulting in anti-oxidative effects on H9c2 cells that attenuated apoptosis.
Keywords ECP reactive oxygen species Akt ERK
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2015-06
Volume volume69
Issue issue3
Publisher Okayama University Medical School
Start Page 145
End Page 153
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26101190
Web of Science KeyUT 000356903000003
JaLCDOI 10.18926/AMO/53520
FullText URL 69_3_137.pdf
Author Seki, Hiroyuki| Ikeda, Fusao| Nanba, Shintaro| Moritou, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Onishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Nakamura, Minoru| Yamamoto, Kazuhide|
Abstract A predictive marker of the rapid progression to hepatic failure is desired for patients with asymptomatic primary biliary cirrhosis (aPBC). We performed a systematic cohort analysis of 101 patients diagnosed as having aPBC and the rapid progression to liver failure in some, by focusing on cholestasis. Cholestasis was assessed by aberrant keratin7 (K-7) expressions in the patientsʼ hepatocytes. Intralobular expressions of K-7 were found in 9 of the 101 patients. The grades of K-7 expression were significantly associated with the levels of alanine aminotransferase, alkaline phosphatase, and total bilirubin at the time of diagnosis, but not with bile duct loss or cholestasis. Stepwise logistic regression analysis revealed that high grades of K-7 expression correlated positively with high levels of total bilirubin. During the follow-up period, 8 patients developed jaundice, and the mean period until the development of jaundice was 5.2 years. The proportional hazards models for the risk of developing jaundice identified a high grade of aberrant K-7 expression in hepatocytes as the only significant risk factor. Aberrant K-7 expression in hepatocytes can be used as an additional marker to predict rapid progression to liver failure in patients with aPBC at the time of diagnosis.
Keywords primary biliary cirrhosis keratin 7 hepatic failure
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2015-06
Volume volume69
Issue issue3
Publisher Okayama University Medical School
Start Page 137
End Page 144
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26101189
Web of Science KeyUT 000356903000002
JaLCDOI 10.18926/AMO/53519
FullText URL 69_3_129.pdf
Author Akagi, Satoshi| Nakamura, Kazufumi| Matsubara, Hiromi| Ogawa, Aiko| Sarashina, Toshihiro| Ejiri, Kentaro| Ito, Hiroshi|
Abstract Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.
Keywords pulmonary arterial hypertension epoprostenol high-dose complications side effects
Amo Type Review
Publication Title Acta Medica Okayama
Published Date 2015-06
Volume volume69
Issue issue3
Publisher Okayama University Medical School
Start Page 129
End Page 136
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26101188
Web of Science KeyUT 000356903000001
Author Zamami, Yoshito| Takatori, Shingo| Goda, Mitsuhiro| Koyama, Toshihiro| Iwatani, Yukiko| Jin, Xin| Takada-Doi, Shima| Kawasaki, Hiromu|
Published Date 2008-11-01
Publication Title Biological & Pharmaceutical Bulletin
Volume volume31
Issue issue11
Content Type Journal Article
Author Zamami, Yoshito| Takatori, Shingo| Koayama, Toshihiro| Goda, Mitsuhiro| Iwatani, Yukiko| Doi, Shima| Kawasaki, Hiromu|
Published Date 2007-12-01
Publication Title 藥學雜誌
Volume volume127
Issue issue12
Content Type Journal Article
Author Zamami, Yoshito| Takatori, Shingo| Iwatani, Yukiko| Yamawaki, Kosuke| Miyashita, Satoko| Yabumae, Nana| Takayama, Fusako| Mio, Mitsunobu| Kawasaki, Hiromu|
Published Date 2008-03-01
Publication Title 藥學雜誌
Volume volume128
Issue issue3
Content Type Journal Article
Author Zamami, Yoshito| Fujiwara, Hiroki| Hosoda, Miho| Hino, Hayato| Hirai, Kazuhiro| Okamoto, Kazuaki| 金 鑫| 高取 真吾| 高木 志真| Kawasaki, Hiromu|
Published Date 2010-06-01
Publication Title 藥學雜誌
Volume volume130
Issue issue6
Content Type Journal Article
Author 全 成坤|
Published Date 2014-03-31
Publication Title 岡山大学文学部プロジェクト研究報告書
Volume volume21
Content Type Research Paper
Author 宋 浣範|
Published Date 2014-03-31
Publication Title 岡山大学文学部プロジェクト研究報告書
Volume volume21
Content Type Research Paper
Author Suzuki, Michitaka|
Published Date 2014-03-31
Publication Title 岡山大学文学部プロジェクト研究報告書
Volume volume21
Content Type Research Paper
Author Watanabe, Yoshinari|
Published Date 2014-03-31
Publication Title 岡山大学文学部プロジェクト研究報告書
Volume volume21
Content Type Research Paper
Author Yusa, Toru|
Published Date 2014-03-31
Publication Title 岡山大学文学部プロジェクト研究報告書
Volume volume21
Content Type Research Paper
Author Watanabe, Yoshinari|
Published Date 2015-03-31
Publication Title 岡山大学文学部プロジェクト研究報告書
Volume volume22-2
Content Type Research Paper
Author Suzuki, Michitaka|
Published Date 2015-03-31
Publication Title 岡山大学文学部プロジェクト研究報告書
Volume volume22-2
Content Type Research Paper
Author 岡山大学文学部|
Published Date 2015-03-31
Publication Title 岡山大学文学部プロジェクト研究報告書
Volume volume22-2
Content Type Others
Author Hanaya, Tadashi| Ito, Kasumi|
Published Date 2014-04
Publication Title Heterocycles
Volume volume88
Issue issue2
Content Type Journal Article
Author Okayama Association for Laboratory Animal Science|
Published Date 2015-04
Publication Title 岡山実験動物研究会報
Volume volume31
Content Type Others
Author Okayama Association for Laboratory Animal Science|
Published Date 2015-04
Publication Title 岡山実験動物研究会報
Volume volume31
Content Type Others
Published Date 2015-04
Publication Title 岡山実験動物研究会報
Volume volume31
Content Type Others
Author Usuda, Toshiki| Furumoto, Kayo| Kita, Megumu|
Published Date 2015-04
Publication Title 岡山実験動物研究会報
Volume volume31
Content Type Journal Article